Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus

Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need f...

Descripción completa

Detalles Bibliográficos
Autores principales: Makari, Doris, Checchia, Paul A, DeVincenzo, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130285/
https://www.ncbi.nlm.nih.gov/pubmed/24316863
http://dx.doi.org/10.4161/hv.27426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130285/
https://www.ncbi.nlm.nih.gov/pubmed/24316863
http://dx.doi.org/10.4161/hv.27426

Ejemplares similares